Comparing radiation with BCG therapy for high-risk bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two standard treatments for a type of early-stage bladder cancer that has a high chance of coming back. It tests whether radiation therapy combined with a drug that makes cancer cells more sensitive to radiation works as well as or better than BCG, which is a special treatment put directly into the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of high-risk non-muscle invasive bladder cancer, which may include carcinoma in situ.
- You are fit to receive either BCG therapy or radiation therapy with a radiosensitizer.
- Your doctor believes you are likely to live for at least another 12 months.
- You are generally able to care for yourself (ECOG performance status 0-2).
- You are 16 years of age or older.
- You have not had previous radiation to the pelvis, previous intravesical therapy, or poor bladder function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether radiation therapy can help people with early-stage bladder cancer that has a high risk of coming back. It may be an option for those who have not tried BCG treatment.
This trial tests whether radiation therapy (high-energy beams to kill cancer cells) can be a good treatment for bladder cancer that hasn't gone away after BCG therapy, offering an alternative to surgery to remove the bladder. It aims to see if this approach can control the cancer while possibly preserving your bladder.
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Hear when a new High Risk Non-muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.